ONWARD
ONWARD today announced the publication of a study in the journal, Nature , which found targeted electrical spinal cord stimulation stabilizes blood pressure in people with spinal cord injury (SCI).
“A serious and underrecognized result of spinal cord injury is unstable blood pressure, which can have devastating consequences that reduce quality of life and are life threatening. Unfortunately, there are no effective therapies for unstable blood pressure after spinal cord injury,” said Dr. Aaron Phillips, PhD, a member of the Hotchkiss Brain Institute and Libin Cardiovascular Institute at the Cumming School of Medicine (CSM) and co-lead author of the study. “We created the first platform to understand the mechanisms underlying blood pressure instability after spinal cord injury, which allowed us to develop a new cutting-edge solution.”
Loss of movement and sensation are the most commonly known impacts of spinal cord injury, but SCI is also frequently accompanied by other effects that challenge activities of daily living. Blood pressure instability is one such effect, making it difficult for people with SCI to change body position – moving from lying to sitting to standing. In this study, researchers from University of Calgary, Swiss Federal Institute of Technology (EPFL), and University Hospital Lausanne (CHUV) demonstrated they could quickly and accurately normalize blood pressure with electrical spinal cord stimulation. Stabilization was observed in rodents and non-human primates for extended periods after acute and chronic spinal cord injury, and the approach also showed promise in humans.
This research is a breakthrough in the fundamental understanding of how blood pressure regulatory circuits function in people with SCI and sets the foundation for further studies assessing the use of electrical spinal cord stimulation to regulate blood pressure and other autonomic functions in people with SCI.
“We used similar concepts and technologies to restore walking after paralysis and are now pleased to leverage those advances to address this very common but serious effect of SCI,” said Dr. Grégoire Courtine, PhD, Professor at EPFL, Director of .NeuroRestore, and co-lead author of the study. “We look forward to working with ONWARD to conduct clinical trials in humans so this approach can be translated into a viable therapeutic option for people with SCI.”
This research will be further advanced by a $36 million contract granted by the United States Defense Advanced Research Project Agency (DARPA) for a five-year project to develop neurotherapeutics that bridge the gap between the spinal cord and the brain after spinal cord injury. The DARPA contract enables an alliance of 12 institutions around the world that includes EPFL, University of Calgary and ONWARD to conduct groundbreaking research in the pursuit of new therapies for spinal cord injury. DARPA has helped develop major technological advancements including the internet, GPS and Speech Interpretation and Recognition Interface (SIRI.)
About ONWARD
ONWARD (@onwdempowered ), formerly known as GTX Medical, is a medical technology company focused on the development and commercialization of innovative therapies to facilitate functional recovery of people with spinal cord injury. Driven by a mission to restore movement, independence, and health in people with spinal cord injury, ONWARD’s work builds on more than a decade of basic science and preclinical research conducted at the world’s leading neuroscience laboratories. ONWARD’s ARC Therapy, which can be delivered by implantable (ARCIM ) or external (ARCEX ) systems, is designed to deliver targeted, programmed stimulation of the spinal cord to restore movement and other functions in people with spinal cord injury, ultimately improving their quality of life. Both of ONWARD’s technology platforms have been awarded Breakthrough Device Designation by the FDA.
ONWARD is headquartered at the High Tech Campus in Eindhoven, the Netherlands and the EPFL Innovation Park in Lausanne, Switzerland, with a growing U.S. presence in Boston, Massachusetts, USA. For additional information about the company, please visit ONWD.com and follow us on Twitter and LinkedIn .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210127005140/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
U.K. Continues to Lead Europe in Shareholder Activism with 44% Year-on-Year Surge, According to Diligent Market Intelligence6.11.2025 13:00:00 CET | Press release
As the U.K. Market Fuels Growing Interest from Domestic and International Activists, Investors Have Adapted their Approach to Gain Access to Boardrooms in Germany and Italy The U.K. remains Europe’s most active market for shareholder activism, with a 44% year-on-year increase in targeted companies, according to the Corporate Governance in Europe 2025report by Diligent Market Intelligence (DMI). Between September 2024 and August 2025, 52 U.K. companies faced activism, compared to 36 over the same timeframe in 2024, underscoring the market’s heightened shareholder engagement. “The U.K. remains the primary driver of public-facing engagement in Europe, with other European markets increasingly witnessing similar strategies when behind-the-scenes efforts fail,” said Josh Black, Editor-in-Chief, Diligent Market Intelligence. “Activism in Europe runs the full gamut from hostile media campaigns to more private engagements but there is no doubt that boards should prepare for anything in what loo
BeOne Medicines Announces Third Quarter 2025 Financial Results and Business Updates6.11.2025 12:00:00 CET | Press release
Third quarter total revenues increased 41% to $1.4 billion versus third quarter 2024Global BRUKINSA® (zanubrutinib) revenues increased 51% to $1.0 billion versus third quarter 2024Diluted GAAP Earnings per American Depository Share (ADS) of $1.09, non-GAAP diluted Earnings per ADS of $2.6547 abstracts accepted at American Society of Hematology (ASH) Annual Meeting BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced financial results and corporate updates from the third quarter of 2025. “These strong financial results reinforce our position as a global oncology leader with exceptional topline growth and a strong balance sheet,” said John V. Oyler, Co-Founder, Chairman and CEO at BeOne. “BRUKINSA is now the global revenue leader in the BTKi class, supported by long-term efficacy and safety data and a growing body of evidence reinforcing its scientific hypothesis of sustained BTK inhibition. Our late-stage hematology portfolio continues
Shippeo Launches Shippeo AI, Turning Trusted Visibility Into Instant, Intelligent Action6.11.2025 12:00:00 CET | Press release
New AI layer, built on the industry's only SLA-backed data, empowers users to resolve supply chain issues in seconds Shippeo, the leading provider of real-time transportation visibility (RTTV), revealed Shippeo AI today, at its Visibility Now! conference. This brand new intelligent layer of the Shippeo Platform delivers trusted visibility and instant action to empower the people behind global supply chains. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251106263715/en/ Alongside Shippeo AI, the company revealed a series of product enhancements: an all-new eCMR (Electronic Consignment Note) system; transformed Air Visibility; a deeper user experience for Finished Vehicle Logistics (FVL); and enhanced data accessibility and UX for the Shippeo platform. This raft of innovations reinforces Shippeo’s position as the world’s most trusted multimodal visibility platform. Shippeo AI, for people who keep the world moving… faster Ship
Wireless Mobility Automotive becomes a 100% German-owned company strengthening its role as a trusted Western supplier6.11.2025 11:49:00 CET | Press release
Wireless Mobility, a leading provider of advanced cellular, automotive, smart and short-range modules, today announces that Wireless Mobility Automotive has become a wholly owned subsidiary of Wireless Mobility Holding GmbH, making the company a 100% German-owned enterprise. This milestone reinforces the company’s position as a transparent and independent Western supplier, fully aligned with the US connected vehicle ecosystem and addressing the expectations of global OEMs and tier one suppliers seeking reliable long-term partners. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251021160513/en/ Norbert Muhrer, CEO, Wireless Mobility “This step underlines our clear commitment to transparency, independence and European quality,” said Norbert Muhrer, CEO of Wireless Mobility. “With German ownership, European engineering, and a global perspective, Wireless Mobility is ready to be the trusted Western supplier the industry has been
Expereo Appoints Noel Hamill as Chief Marketing Officer6.11.2025 10:00:00 CET | Press release
Expereo, the world-leading managed Network as a Service (NaaS) provider that connects people, places and things anywhere, today announces the appointment of Noel Hamill as its Chief Marketing Officer (CMO), a strategic hire to accelerate the company’s growth strategy. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251106364284/en/ Noel Hamill Hamill joins Expereo with over two decades of marketing leadership experience across global SaaS businesses and consumer brands, including EE and Ladbrokes, PG Forsta and most recently parcelLab, where he served as CMO. In his new role, Hamill will report directly to Ben Elms, CEO, and lead Expereo’s global marketing strategy with a sharp focus on driving growth, expanding market share, and scaling customer acquisition across enterprise and wholesale segments. His appointment underscores Expereo’s commitment to strengthening its brand presence and accelerating adoption of its expereoOne
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom